DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Questions
Schema
Social Networks
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We began analyzing https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1007/s13148-011-0041-7, but it redirected us to https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1007/s13148-011-0041-7. The analysis below is for the second page.

Title[redir]:
Epigenetic regulation of prostate cancer | Clinical Epigenetics | Full Text
Description:
Prostate cancer is a commonly diagnosed cancer in men and a leading cause of cancer deaths. Whilst the underlying mechanisms leading to prostate cancer are still to be determined, it is evident that both genetic and epigenetic changes contribute to the development and progression of this disease. Epigenetic changes involving DNA hypo- and hypermethylation, altered histone modifications and more recently changes in microRNA expression have been detected at a range of genes associated with prostate cancer. Furthermore, there is evidence that particular epigenetic changes are associated with different stages of the disease. Whilst early detection can lead to effective treatment, and androgen deprivation therapy has a high response rate, many tumours develop towards hormone-refractory prostate cancer, for which there is no successful treatment. Reliable markers for early detection and more effective treatment strategies are, therefore, needed. Consequently, there is a considerable interest in the potential of epigenetic changes as markers or targets for therapy in prostate cancer. Epigenetic modifiers that demethylate DNA and inhibit histone deacetylases have recently been explored to reactivate silenced gene expression in cancer. However, further understanding of the mechanisms and the effects of chromatin modulation in prostate cancer are required. In this review, we examine the current literature on epigenetic changes associated with prostate cancer and discuss the potential use of epigenetic modifiers for treatment of this disease.

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🚄 Respectable Traffic: 10k - 20k visitors per month

Based on our best estimate, this website will receive around 10,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We see no obvious way the site makes money.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Doi.org might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

cancer, prostate, pubmed, google, scholar, dna, cell, expression, methylation, gene, cells, hypermethylation, histone, study, genes, tumour, lines, found, gstp, treatment, human, promoter, res, samples, central, epigenetic, studies, mirnas, hypomethylation, progression, tumours, growth, lncap, individuals, combination, potential, levels, modifications, androgen, cpg, patients, effects, metastatic, vivo, metastasis, hkme, mice, clin, cancers, inhibitors,

Topics {✒️}

pi-class glutathione s-transferase π-class glutathione-s-transferase promote androgen-receptor-dependent transcription tnfalpha-related apoptosis-inducing ligand post-prostate massage-voided urine tumor suppressor pten/mmac1 lymph-node-positive prostate cancers prostate-tumour-bearing mouse model cyclin-dependent kinase 2a hormone-independent cell lines stimulating ar-dependent transcription hormone-refractory prostate cancer ar-positive cell lines androgen-independent cell lines hormone-refractory prostate cancers s100 calcium-binding protein cd44 + alpha2beta1+ cell population free prostate-specific antigen retinoid-resistant prostate cancer castration-resistant prostate cancer ar-negative cell lines hif-1alpha/hif-1beta p53-defective cell lines hormone-independent prostate cancer cell-free circulating dna open access article increased cell-free dna quantitative methylation-specific pcr prostate cancer-related proteins androgen-independent prostate cancer develop androgen-independent status gene-specific hypermethylation events gene-specific hypomethylation events cell-free plasma dna cell-free dna hypermethylation cell-free dna appears rarβ2 promoter-luciferase gene multi-platform mirna screening cancer-related genomic regions polycomb repression signature late-stage prostate cancer demonstrated anti-tumourigenic activities privacy choices/manage cookies prostate cancer-specific genes prostate-cancer-specific genes ectopic mir-34a expression demethylating agent 5-aza-2′deoxycitidine nucleoside inhibitor 5-aza-2′-deoxycytidine decitabine-mediated gene expression human cell lines

Questions {❓}

Brothman AR, Swanson G, Maxwell TM, Cui J, Murphy KJ, Herrick J, Speights VO, Isaac J, Rohr LR (2005) Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome?
Halliwell B (2006) Oxidative stress and neurodegeneration: where are we now?
Schwartz G, Hulka B (1990) Is vitamin D deficiency a risk factor for prostate cancer?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Epigenetic regulation of prostate cancer
         description:Prostate cancer is a commonly diagnosed cancer in men and a leading cause of cancer deaths. Whilst the underlying mechanisms leading to prostate cancer are still to be determined, it is evident that both genetic and epigenetic changes contribute to the development and progression of this disease. Epigenetic changes involving DNA hypo- and hypermethylation, altered histone modifications and more recently changes in microRNA expression have been detected at a range of genes associated with prostate cancer. Furthermore, there is evidence that particular epigenetic changes are associated with different stages of the disease. Whilst early detection can lead to effective treatment, and androgen deprivation therapy has a high response rate, many tumours develop towards hormone-refractory prostate cancer, for which there is no successful treatment. Reliable markers for early detection and more effective treatment strategies are, therefore, needed. Consequently, there is a considerable interest in the potential of epigenetic changes as markers or targets for therapy in prostate cancer. Epigenetic modifiers that demethylate DNA and inhibit histone deacetylases have recently been explored to reactivate silenced gene expression in cancer. However, further understanding of the mechanisms and the effects of chromatin modulation in prostate cancer are required. In this review, we examine the current literature on epigenetic changes associated with prostate cancer and discuss the potential use of epigenetic modifiers for treatment of this disease.
         datePublished:2011-06-14T00:00:00Z
         dateModified:2011-06-14T00:00:00Z
         pageStart:151
         pageEnd:169
         license:https://creativecommons.org/licenses/by/2.0
         sameAs:https://doi.org/10.1007/s13148-011-0041-7
         keywords:
            Prostate cancer
            Epigenetics
            DNA methylation
            Histone acetylation
            MicroRNA
            Human Genetics
            Gene Function
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13148-011-0041-7/MediaObjects/13148_2011_41_Article_Fig1_HTML.gif
         isPartOf:
            name:Clinical Epigenetics
            issn:
               1868-7083
               1868-7075
            volumeNumber:2
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Suyin P. Chin
               affiliation:
                     name:University of Tasmania
                     address:
                        name:Menzies Research Institute Tasmania, University of Tasmania, Hobart, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Joanne L. Dickinson
               affiliation:
                     name:University of Tasmania
                     address:
                        name:Menzies Research Institute Tasmania, University of Tasmania, Hobart, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Adele F. Holloway
               affiliation:
                     name:University of Tasmania
                     address:
                        name:Menzies Research Institute Tasmania, University of Tasmania, Hobart, Australia
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Epigenetic regulation of prostate cancer
      description:Prostate cancer is a commonly diagnosed cancer in men and a leading cause of cancer deaths. Whilst the underlying mechanisms leading to prostate cancer are still to be determined, it is evident that both genetic and epigenetic changes contribute to the development and progression of this disease. Epigenetic changes involving DNA hypo- and hypermethylation, altered histone modifications and more recently changes in microRNA expression have been detected at a range of genes associated with prostate cancer. Furthermore, there is evidence that particular epigenetic changes are associated with different stages of the disease. Whilst early detection can lead to effective treatment, and androgen deprivation therapy has a high response rate, many tumours develop towards hormone-refractory prostate cancer, for which there is no successful treatment. Reliable markers for early detection and more effective treatment strategies are, therefore, needed. Consequently, there is a considerable interest in the potential of epigenetic changes as markers or targets for therapy in prostate cancer. Epigenetic modifiers that demethylate DNA and inhibit histone deacetylases have recently been explored to reactivate silenced gene expression in cancer. However, further understanding of the mechanisms and the effects of chromatin modulation in prostate cancer are required. In this review, we examine the current literature on epigenetic changes associated with prostate cancer and discuss the potential use of epigenetic modifiers for treatment of this disease.
      datePublished:2011-06-14T00:00:00Z
      dateModified:2011-06-14T00:00:00Z
      pageStart:151
      pageEnd:169
      license:https://creativecommons.org/licenses/by/2.0
      sameAs:https://doi.org/10.1007/s13148-011-0041-7
      keywords:
         Prostate cancer
         Epigenetics
         DNA methylation
         Histone acetylation
         MicroRNA
         Human Genetics
         Gene Function
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13148-011-0041-7/MediaObjects/13148_2011_41_Article_Fig1_HTML.gif
      isPartOf:
         name:Clinical Epigenetics
         issn:
            1868-7083
            1868-7075
         volumeNumber:2
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Suyin P. Chin
            affiliation:
                  name:University of Tasmania
                  address:
                     name:Menzies Research Institute Tasmania, University of Tasmania, Hobart, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Joanne L. Dickinson
            affiliation:
                  name:University of Tasmania
                  address:
                     name:Menzies Research Institute Tasmania, University of Tasmania, Hobart, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Adele F. Holloway
            affiliation:
                  name:University of Tasmania
                  address:
                     name:Menzies Research Institute Tasmania, University of Tasmania, Hobart, Australia
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Clinical Epigenetics
      issn:
         1868-7083
         1868-7075
      volumeNumber:2
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Tasmania
      address:
         name:Menzies Research Institute Tasmania, University of Tasmania, Hobart, Australia
         type:PostalAddress
      name:University of Tasmania
      address:
         name:Menzies Research Institute Tasmania, University of Tasmania, Hobart, Australia
         type:PostalAddress
      name:University of Tasmania
      address:
         name:Menzies Research Institute Tasmania, University of Tasmania, Hobart, Australia
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Suyin P. Chin
      affiliation:
            name:University of Tasmania
            address:
               name:Menzies Research Institute Tasmania, University of Tasmania, Hobart, Australia
               type:PostalAddress
            type:Organization
      name:Joanne L. Dickinson
      affiliation:
            name:University of Tasmania
            address:
               name:Menzies Research Institute Tasmania, University of Tasmania, Hobart, Australia
               type:PostalAddress
            type:Organization
      name:Adele F. Holloway
      affiliation:
            name:University of Tasmania
            address:
               name:Menzies Research Institute Tasmania, University of Tasmania, Hobart, Australia
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Menzies Research Institute Tasmania, University of Tasmania, Hobart, Australia
      name:Menzies Research Institute Tasmania, University of Tasmania, Hobart, Australia
      name:Menzies Research Institute Tasmania, University of Tasmania, Hobart, Australia

Social Networks {👍}(2)

External Links {🔗}(654)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Prism.js

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

CDN Services {📦}

Crossref

5.35s.